本帖最后由 老马 于 2012-1-13 21:20 编辑 & Z) V2 W( |$ ^) u, z% S2 H1 c5 N
' b5 r; A: R6 n2 e- _! P/ r
爱必妥和阿瓦斯丁的比较
9 G0 X X: e1 M) V6 Z$ M
4 C0 J @9 F- U1 _% n" n+ N5 Dhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/* c; P+ M# `; x1 B
! u" N- y }/ d8 p
0 A6 `8 F% n5 e- o
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/! K( }, C- A% Y1 Y: t' f3 h
==================================================
# `/ T3 R/ X, G$ z9 v2 R- bOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
: g1 w4 i5 F% Z, ?Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
- I* N& w- b+ D8 dResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
& i9 W5 x% f5 R0 d" Q3 B+ y& A
|